Journal of Nutrition EB Program 2010 Early Registration

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Densupsoontorn, N.
Right arrow Articles by Deckelbaum, R. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Densupsoontorn, N.
Right arrow Articles by Deckelbaum, R. J.
© 2008 American Society for Nutrition J. Nutr. 138:257-261, February 2008


Biochemical, Molecular, and Genetic Mechanisms

CD36 and Proteoglycan-Mediated Pathways for (n-3) Fatty Acid–Enriched Triglyceride-Rich Particle Blood Clearance in Mouse Models In Vivo and in Peritoneal Macrophages In Vitro1,2

Narumon Densupsoontorn3,5, Yvon A. Carpentier4, Radjini Racine5, Faith M. Murray5, Toru Seo5, Rajasekhar Ramakrishnan5,6 and Richard J. Deckelbaum5,6,*

3 Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand; 4 Laboratory for Experimental Surgery, Universite Libre de Bruxelles, Brussels 1070, Belgium; and 5 Institute of Human Nutrition and 6 Department of Pediatrics, College of Physicians and Surgeons, Columbia University, New York, NY 10032

* To whom correspondence should be addressed. E-mail: rjd20{at}columbia.edu.

Because the mechanisms of (n-3) fatty acid–enriched triglyceride-rich particle [(n-3)-TGRP] uptake are not well characterized, we questioned whether (n-3)-TGRP are removed via "nonclassical" pathways, e.g., pathways other than an LDL receptor and/or involving apolipoprotein E (apoE). Chylomicron-sized model (n-3)-TGRP labeled with [3H]cholesteryl ether were injected into wild-type (WT) and CD36 knockout (CD36–/–) mice at low, nonsaturating and high, saturating doses. Blood clearance of (n-3)-TGRP was determined by calculating fractional catabolic rates. At saturating doses, blood clearance of (n-3)-TGRP was slower in CD36–/– mice relative to WT mice, suggesting that in part CD36 contributes to (n-3)-TGRP uptake. To further examine the potential nonclassical clearance pathways, peritoneal-elicited macrophages from WT and CD36–/– mice were incubated with (n-3)-TGRP in the presence of apoE, lactoferrin, and/or sodium chlorate. Cellular (n-3)-TGRP uptake was measured to test the roles of apoE-mediated pathways and/or proteoglycans. ApoE-mediated pathways compensated in part for defective (n-3)-TGRP uptake in CD36–/– cells. Lactoferrin decreased (n-3)-TGRP uptake in the presence of apoE. Inhibition of cell proteoglycan synthesis by chlorate reduced (n-3)-TGRP uptake in both groups of macrophages, and chlorate effects were independent of apoE. We conclude that although CD36 is involved, it is not the primary contributor to the blood clearance of (n-3)-TGRP. The removal of (n-3)-TGRP likely relies more on nonclassical pathways, such as proteoglycan-mediated pathways.





This article has been cited by other articles:


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
M. Febbraio
CD36 Goes Native
Arterioscler Thromb Vasc Biol, July 1, 2008; 28(7): 1209 - 1210.
[Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Copyright © 2008 by American Society for Nutrition